Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+०.२८%
१,०८५.८१
+३.०१
+०.२८%
१,०८२.८०१,०७९.३११,०९०.१८१,०७९.३१
SIXC
Communications
SIXC
Communications
SIXC
+०.६५%
६०७.६९
+३.९२
+०.६५%
६०३.७७६०३.७७६११.६५६०२.०९
SIXE
Energy
SIXE
Energy
SIXE
-१.५५%
१,१९२.३८
-१८.८१
-१.५५%
१,२११.१९१,२०३.०५१,२०३.४८१,१८२.७२
SIXI
Industrials
SIXI
Industrials
SIXI
+०.०२%
१,७५६.३९
+०.४०
+०.०२%
१,७५५.९९१,७५९.०६१,७६१.७४१,७४७.२३
SIXM
Financials
SIXM
Financials
SIXM
-०.८२%
६३३.२७
-५.२४
-०.८२%
६३८.५१६३७.९३६४०.१०६३१.८९
SIXR
Staples
SIXR
Staples
SIXR
+१.१२%
८५२.४२
+९.४६
+१.१२%
८४२.९६८४३.५४८५८.४४८४३.५४
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.२२%
२१८.७९
-०.४९
-०.२२%
२१९.२८२१९.२८२२०.५८२१८.६४
SIXT
Technology
SIXT
Technology
SIXT
-०.४५%
३,७११.६९
-१६.६६
-०.४५%
३,७२८.३५३,७४५.०६३,७४५.०६३,६७५.०२
SIXU
Utilities
SIXU
Utilities
SIXU
-०.४८%
९११.०५
-४.४३
-०.४८%
९१५.४८९१४.४९९१५.८४९०७.९०
SIXV
Health care
SIXV
Health care
SIXV
+०.२२%
१,५००.६६
+३.३०
+०.२२%
१,४९७.३६१,५००.६५१,५१४.७०१,४९५.८९
SIXY
Discretionary
SIXY
Discretionary
SIXY
+१.७३%
२,४५४.९६
+४१.७९
+१.७३%
२,४१३.१७२,४३१.६९२,४६३.५२२,४३१.६९
AMG:ETR
Amgen Inc
€ २९२.३५
०.००%
(०.००) 1D
मे २७, १७:३५:४१ GMT+२  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for AMG...
Mkt. cap
१.८१ खरब
Avg. vol.
३६०.००
Volume
०.००
52-wk high
€ ३३३.००
52-wk low
€ २३०.००
No. of employees
३२ हजार
News stories
From sources across the web
Yahoo Finance
Yahoo Finance
·
१६ घण्टा पहिले
Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
Stock Titan
Stock Titan
·
१७ घण्टा पहिले
Ember raises $27M to tackle drug and vaccine losses in cold chain
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees३१.५ हजार
Founded१९८० अप्रिल ८
Headquartersथाउजेन्ड ओक्स, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websiteamgen.com
Last report
२०२६ अप्रिल ३०
Fiscal period
Q1 2026
EPS / Est. (USD)
US$ ५.१५ / US$ ४.७७
+८.०४%beat
Revenue / Est. (USD)
८.६२ अरब / ८.५७ अरब
+०.५५%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
Revenue
९.१८ अरब
९.५६ अरब
९.८७ अरब
८.६२ अरब
Cost of goods sold
२.६७ अरब
२.७४ अरब
२.६८ अरब
२.५० अरब
Cost of revenue
२.६७ अरब
२.७४ अरब
२.६८ अरब
२.५० अरब
Research and development expenses
१.७४ अरब
१.९० अरब
२.१४ अरब
१.७२ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.६९ अरब
१.७२ अरब
१.९५ अरब
१.६० अरब
Operating expense
३.५० अरब
३.५५ अरब
४.१८ अरब
३.२१ अरब
Total operating expenses
६.१८ अरब
६.२९ अरब
६.८५ अरब
५.७० अरब
Operating income
३.०० अरब
३.२६ अरब
३.०१ अरब
२.९१ अरब
Other non operating income
-११.३० करोड
१८.१० करोड
१४.३० करोड
१९.२० करोड
EBT including unusual items
१.५७ अरब
३.९२ अरब
१.५१ अरब
२.०८ अरब
EBT excluding unusual items
२.३७ अरब
२.७२ अरब
२.५१ अरब
२.३७ अरब
Income tax expense
१३.६० करोड
७०.५० करोड
१८.१० करोड
२६.५० करोड
Effective tax rate
८.६७%
१७.९८%
११.९६%
१२.७२%
Other operating expenses
६.८० करोड
-७.१० करोड
८.२० करोड
-११.३० करोड
Net income
१.४३ अरब
३.२२ अरब
१.३३ अरब
१.८२ अरब
Net profit margin
१५.६०%
३३.६५%
१३.५१%
२१.११%
Earnings per share
६.०२
५.६४
५.२९
५.१५
Interest and investment income
-
-
४०.८० करोड
-
Interest expense
-६९.४० करोड
-६८.५० करोड
-१.०६ अरब
-६५.७० करोड
Net interest expenses
-६९.४० करोड
-६८.५० करोड
-६५.३० करोड
-६५.७० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
४.३४ अरब
४.५७ अरब
४.०२ अरब
४.०३ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more